As India and Japan seek to build on long-standing diplomatic and strategic ties, biopharma executives at a recent event highlighted the need for greater “alignment” on the regulatory front and also certain partnering initiatives that have made an impact during the pandemic. Efforts for wider co-operation between the two nations to ensure supply chain resilience also appear to be building up.
Addressing the “India-Japan CEO Speak Series on Bilateral Economic Cooperation,” Ichiro Fujikawa, CEO of wholesaler/distributor Fujikawa & Co. Ltd., suggested that moving towards a mutual recognition agreement (MRA) in the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?